NCT05469126

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3502970	Administered orally.
DRUG	Clarithromycin	Administered orally.

Timeline

• Start date: 2022-08-01
• Primary completion: 2022-11-03
• Completion: 2022-11-03
• First posted: 2022-07-21
• Last updated: 2022-11-25

Locations

1 site across 1 country: Singapore